Sandoz selects three finalists for Healthcare Access Challenge (Sandoz HACk) from over 400 global entries

  • Competition generated ideas from more than 400 entrants in 80 countries – three shortlisted entrants from Uganda, the US and the Netherlands
  • Three finalists shared innovative uses of artificial intelligence, mobile apps and digital therapeutics to address local healthcare access challenges
  • Finalists will participate in a four-day “accelerator event” in March, collaborating with Sandoz to further refine their ideas, immediately ahead of final judging

Holzkirchen, January 16, 2019 – Sandoz, a Novartis division, …

/by

Sandoz and Pear Therapeutics Announce US Launch of reSET-OTM to Help Treat Opioid Use Disorder

  • reSET-O(TM)* is the first US FDA-cleared prescription digital therapeutic for patients with Opioid Use Disorder
  • Cleared by the FDA in December, reSET-O is available immediately
  • As part of a broader focus on digital healthcare solutions at Novartis, Sandoz aims to increase patient engagement and improve access to treatment through digital solutions

HOLZKIRCHEN, January 7, 2018 – Sandoz Inc., a Novartis division, and Pear Therapeutics, Inc., announced today the US commercial launch of reSET-O(TM) for patients with Opioid Use Disorder (OUD …

/by

Sandoz enters into commercialization and supply agreement for insulin biosimilars, anticipating growing demand as diabetes burden rises

  • Agreement covers biosimilar insulins in early and clinical development for the top three selling branded insulins by sales: glargine, lispro and aspart
  • Over 400 million people worldwide have diabetes and the amount of insulin required to treat type 2 diabetes alone is expected to increase by more than 20% from 2018 to 2030[1],[2]
  • Sandoz continues to strategically expand their biosimilars portfolio, with eight marketed biosimilars and a robust pipeline, showing ongoing commitment to accessible innovation

…

/by

Sandoz teams up to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR)

  • Strategic collaboration agreement with Curetis subsidiary Ares Genetics to develop digital platform for development and life-cycle management of antibiotics
  • Program will combine established microbiology laboratory techniques with advanced bioinformatics and AI methods
  • Short-term focus on repurposing existing antibiotics to treat infections involving multi-drug-resistant pathogens

Holzkirchen, December 18, 2018 – Sandoz today announces the signature of a strategic collaboration agreement with Ares Genetics GmbH, to …

/by

Sandoz Inc. and Pear Therapeutics Obtain FDA Clearance for reSET-O(TM) to Treat Opioid Use Disorder

  • reSET-OTM is the first FDA-cleared Prescription Digital Therapeutic (PDT) for patients with Opioid Use Disorder
  • Pear Therapeutics is leading the development of a new therapeutic class with two FDA-authorized PDTs and a robust pipeline of therapeutics across disease areas
  • Sandoz will lead U.S. commercial launch, anticipated in coming days in Q4
  • As part of broader Novartis digital revolution, Sandoz aims to increase patient engagement and improve access to treatment through digital solutions

…

/by

Sandoz certified Top Employer Asia Pacific 2019

  • Sandoz has been certified by the Top Employers Institute for its exceptional employee offerings in Asia Pacific (APAC)
  • The annual, international research undertaken by the Top Employers Institute recognizes leading employers around the world
  • This exclusive certification underlines Sandoz´ commitment to build a great place to work

Holzkirchen, December 4, 2018 – Sandoz, a Novartis division, has been certified “TOP Employer Asia Pacific 2019” for its exceptional employee offerings in the region. Sandoz is certified in five Asia …

/by

Sandoz receives eighth European Commission approval for a biosimilar with Ziextenzo® (pegfilgrastim)

  • Biosimilar Ziextenzo® (pegfilgrastim), a long-acting version of supportive oncology medicine filgrastim, is now approved for use in all reference medicine indications [1]
  • Ziextenzo is indicated to reduce duration of neutropenia / incidence of febrile neutropenia, some of the most serious side effects of chemotherapy [2]
  • Sandoz demonstrates commitment to making access happen for patients with eight biosimilars approved in EU, including five in last 18 months

Holzkirchen, November 27, 2018 – Sandoz, a Novartis division …

/by

Sandoz and Pear Therapeutics announce launch of reSET® for treatment of patients with Substance Use Disorder

  • reSET® is the first and only FDA-authorized prescription digital therapeutic for Substance Use Disorder (SUD)
  • Adding reSET to outpatient therapy significantly improved abstinence in substances of abuse and treatment retention compared to standard of care alone
  • Sandoz and Novartis continue to embrace digital technologies to enhance R&D and deliver better outcomes for patients

Holzkirchen, November 19, 2018 – Sandoz, a Novartis division, and Pear Therapeutics, Inc., announced today the commercial launch …

/by

Sandoz commits to practical and scalable solutions to combat growing global threat of antimicrobial resistance (AMR)

  • Antibiotics are the cornerstone of modern medicine, but AMR represents an increasingly serious threat to global public health1
  • Sandoz, as the world’s leading provider of high-quality antibiotics, is committed to playing a key role in efforts to balance improved access and responsible use2
  • Focus is on driving practical, scalable on-the-ground solutions across four key areas, to help make a true impact and contribute to agreed global goals3

Holzkirchen, November 7, 2018 – …

/by

Sandoz decides not to pursue US biosimilar rituximab; will focus on robust biosimilar portfolio for unmet access and sustainability needs

  • Decision follows FDA request for additional information to complement submission for biosimilar rituximab
  • Sandoz stands behind safety, efficacy and quality of our biosimilar rituximab, which is already approved in EU, Switzerland, Japan and Australia
  • With seven biosimilars already approved globally, Sandoz will focus on progressing robust pipeline to enable early and expanded patient access and healthcare savings  

 

Holzkirchen, Germany, November 2, 2018 — Sandoz, a Novartis division and the pioneer and global …

/by